[go: up one dir, main page]

WO1994024279A3 - Agents for the prevention and treatment of huntington's disease and other neurological disorders - Google Patents

Agents for the prevention and treatment of huntington's disease and other neurological disorders Download PDF

Info

Publication number
WO1994024279A3
WO1994024279A3 PCT/EP1994/001164 EP9401164W WO9424279A3 WO 1994024279 A3 WO1994024279 A3 WO 1994024279A3 EP 9401164 W EP9401164 W EP 9401164W WO 9424279 A3 WO9424279 A3 WO 9424279A3
Authority
WO
WIPO (PCT)
Prior art keywords
huntington
disease
agents
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1994/001164
Other languages
French (fr)
Other versions
WO1994024279A2 (en
Inventor
Johanna Eugenie Bergmann
Rick E Preddie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2094169 external-priority patent/CA2094169A1/en
Application filed by Individual filed Critical Individual
Priority to AU66781/94A priority Critical patent/AU6678194A/en
Publication of WO1994024279A2 publication Critical patent/WO1994024279A2/en
Publication of WO1994024279A3 publication Critical patent/WO1994024279A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Agents and methods for the diagnosis and therapy of Huntington's Disease and related conditions are disclosed. Such agents include antisense molecules of genes implicated in Huntington's Disease and related diseases as well as analogues and derivatives of these molecules, and protein molecules expressed by these genes.
PCT/EP1994/001164 1993-04-16 1994-04-14 Agents for the prevention and treatment of huntington's disease and other neurological disorders Ceased WO1994024279A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU66781/94A AU6678194A (en) 1993-04-16 1994-04-14 Agents for the prevention and treatment of huntington's disease and other neurological disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2,094,169 1993-04-16
CA 2094169 CA2094169A1 (en) 1993-04-16 1993-04-16 Agents for the prevention and cure of huntington disease in humans: cdna, precursor polypeptide hormone and active hormone reconstructed from the antisense strand of the huntingtondisease gene, "huntingtin"
US5057893A 1993-04-20 1993-04-20
US08/050,578 1993-04-20

Publications (2)

Publication Number Publication Date
WO1994024279A2 WO1994024279A2 (en) 1994-10-27
WO1994024279A3 true WO1994024279A3 (en) 1995-03-30

Family

ID=25676093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/001164 Ceased WO1994024279A2 (en) 1993-04-16 1994-04-14 Agents for the prevention and treatment of huntington's disease and other neurological disorders

Country Status (2)

Country Link
AU (1) AU6678194A (en)
WO (1) WO1994024279A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741645A (en) * 1993-06-29 1998-04-21 Regents Of The University Of Minnesota Gene sequence for spinocerebellar ataxia type 1 and method for diagnosis
US5834183A (en) * 1993-06-29 1998-11-10 Regents Of The University Of Minnesota Gene sequence for spinocerebellar ataxia type 1 and method for diagnosis
CN1076067C (en) 1995-08-03 2001-12-12 欧罗巴金属公开有限公司 Low lead release plumbing components made of copper basedalloys containing lead, and method for obtaining the same
US6093549A (en) * 1995-11-09 2000-07-25 The Johns Hopkins University Huntingtin-associated protein-related assays
EP0873132A4 (en) * 1995-11-17 2002-09-18 Univ British Columbia Binding protein for Huntington's disease gene product, coding cDNA and antibodies
CA2275865C (en) * 1996-08-28 2006-12-12 The Johns Hopkins University School Of Medicine Method for detecting cell proliferative disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERGMANN, J.E. ET AL.: "A protein drp90 encoded on the leftwards strand of soybean nodule urate oxidase cDNA ...", NUCLEIC ACIDS RESEARCH, vol. 19, no. 6, 1991, pages 1338 *
PREDDIE, E. & BERGMANN, J.E.: "A novel protein (suef) programmed by the leftwards starnd of a chimeric cDNA stops the expression of several proteins in E.coli", NUCLEIC ACIDS RESEARCH, vol. 18, no. 21, 1990, pages 6459 *
THE HUNTINGTON'S DESEASE COLLABORATIVE RESEARCH GROUP: "A novel gene containing a trinucleotide repeat that is expanded and unstable in Huntington's disease chromosomes", CELL, vol. 72, 26 March 1993 (1993-03-26), pages 971 - 983 *

Also Published As

Publication number Publication date
WO1994024279A2 (en) 1994-10-27
AU6678194A (en) 1994-11-08

Similar Documents

Publication Publication Date Title
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
TW264480B (en)
AU6406996A (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
IL135315A0 (en) 4(3)-substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (gabapentin analogues), their preparation and their use in the treatment of neurological disorders
WO1997034586A3 (en) Device and method for treating ophthalmic diseases
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
AU3497295A (en) Compositions and methods for the treatment of body weight disorders, including obesity
CA2223776A1 (en) Method of treatment for lung diseases using antisense oligonucleotides
WO2004110360A3 (en) Proteoglycan degrading mutants for treatment of cns
WO2002096415A3 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
WO2002036829A3 (en) Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
HUP9701193A3 (en) Use of n-(4-aryl-thiazol-2-yl)-sulfonamide derivatives for the preparation of pharmaceutical compositions treating neurological disorders, new derivatives, process for their preparation and pharmaceutical compositions containing them
EP0331620A3 (en) Agent for the treatment of parkinson's disease
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
WO2003034996A3 (en) Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
WO1992012715A3 (en) The use of loperamide and related compounds for treatment of respiratory disease symptoms
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
AU3364499A (en) Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
AU4312593A (en) Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease
WO1994024279A3 (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1994914374

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994914374

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase